Optas, LLC Novo Nordisk A S Transaction History

Optas, LLC

$455 Million
Q4 2024

A detailed history of Optas, LLC transactions in Novo Nordisk A S stock. As of the latest transaction made, Optas, LLC holds 6,259 shares of NVO stock, worth $524,128. This represents 0.12% of its overall portfolio holdings.

Number of Shares

6,259

Previous 5,645 10.88%

Holding current value

$524,128

Previous $672,000 19.94%

% of portfolio

0.12%

Previous 0.16%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 24, 2025	BUY	$85.0 - $120.04 $52,190 - $73,704	614 Added 10.88%	6,259 $538,000
Q3 2024 Oct 29, 2024	SELL	$119.07 - $145.42 $14,050 - $17,159	-118 Reduced 2.05%	5,645 $672,000
Q2 2024 Jul 25, 2024	BUY	$122.71 - $146.91 $5,276 - $6,317	43 Added 0.75%	5,763 $822,000
Q1 2024 Apr 17, 2024	BUY	$102.11 - $135.92 $1,633 - $2,174	16 Added 0.28%	5,720 $734,000
Q4 2023 Jan 25, 2024	BUY	$87.78 - $105.45 $25,105 - $30,158	286 Added 5.28%	5,704 $590,000
Q3 2023 Oct 31, 2023	BUY	$90.94 - $199.54 $253,267 - $555,718	2,785 Added 105.77%	5,418 $492,000
Q2 2023 Jul 20, 2023	BUY	$155.98 - $172.65 $12,166 - $13,466	78 Added 3.05%	2,633 $426,000
Q1 2023 Apr 17, 2023	BUY	$132.34 - $159.14 $15,880 - $19,096	120 Added 4.93%	2,555 $406,000
Q4 2022 Jan 27, 2023	BUY	$102.55 - $135.33 $1,128 - $1,488	11 Added 0.45%	2,435 $329,000
Q3 2022 Oct 31, 2022	BUY	$95.28 - $116.93 $6,669 - $8,185	70 Added 2.97%	2,424 $242,000
Q2 2022 Aug 01, 2022	BUY	$103.24 - $121.81 $23,435 - $27,650	227 Added 10.67%	2,354 $263,000
Q1 2022 Apr 26, 2022	BUY	$93.1 - $112.54 $198,023 - $239,372	2,127 New	2,127 $236,000

Others Institutions Holding NVO

# of Institutions

1,879

Shares Held

336M

Call Options Held

11.9M

Put Options Held

10.6M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $189B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Optas, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Optas, LLC with notifications on news.

Account